News

Vemurafenib's Efficacy in Melanoma Wanes Over Time

Publish date: July 3, 2012

 

AT THE ANNUAL MEETING OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

Dr. Chapman disclosed that he receives honoraria and research funding from Roche/Genentech. The trial was sponsored by Hoffman-LaRoche. Dr. Atkins disclosed that he is a consultant to Bristol-Myers Squibb, Celgene, Curetech, Genentech, Merck, Novartis, and Prometheus.

This article was updated on July 3, 2012.

Pages

Recommended Reading

Gains in Melanoma Survival Attributed to Patient Awareness
MDedge Dermatology
Early Detection of Melanoma: Harnessing Untapped Resources
MDedge Dermatology
Women 30% More Likely to Survive Melanoma Than Men
MDedge Dermatology
CDC: Indoor Tanning, Sunburns Still Common in Young Adults
MDedge Dermatology
SCREEN: Melanoma Deaths Reduced by Half in Largest Study Ever
MDedge Dermatology
Vismodegib Proves Promising for Operable BCCs
MDedge Dermatology
Stanford Experience Shows Long Metastatic BCC Survival
MDedge Dermatology
Vismodegib Continues to Prove BCC Effectiveness
MDedge Dermatology
Aspirin Found to Protect Against Melanoma
MDedge Dermatology
Don't Disregard High-Dose Brachytherapy for Skin Cancer
MDedge Dermatology